Publications by authors named "Y Bar"
Article Synopsis
- The ASPIRE intervention aims to enhance the daily life performance of older adults with subjective cognitive decline (SCD) or mild cognitive impairment (MCI) over a 10-week period.
- It was compared to a Brain Education control group to evaluate its effectiveness in improving daily activities and overall satisfaction, along with health-related quality of life and cognitive test performance.
- The study utilized a double-blind, randomized controlled trial design involving 264 older adults, with evaluations conducted over six months to assess the sustainability of any improvements.
Background: Early invasive ductal carcinoma (IDC) breast cancer often presents with a coexisting ductal carcinoma in situ (DCIS) component, while about 5 % of cases present with an extensive (>25 %) intraductal component (EIC). The impact of EIC on the genomic risk of recurrence is unclear.
Methods: Patients with early hormone receptor-positive HER2neu-negative (HR + HER2-) IDC breast cancer and a known OncotypeDX Breast Recurrence Score® (RS) who underwent breast surgery at our institute were included.
We aimed to study the incidence and genomic spectrum of actionable alterations (AA) detected in serial cfDNA collections from patients with metastatic breast cancer (MBC). Patients with MBC who underwent plasma-based cfDNA testing (Guardant360) between 2015 and 2021 at an academic institution were included. For patients with serial draws, new pathogenic alterations in each draw were classified as actionable alterations (AA) if they met ESCAT I or II criteria of the ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT).
View Article and Find Full Text PDFTranslational research in medicine has undergone significant changes in the last decade, primarily due to the remarkable technological advancements made during this period. Oncology research is at the forefront of translational research in medicine and is heavily influenced by these changes. In this article, we briefly review the technologies that form the basis for the "next generation of translational research" in oncology in the coming decades, as well as the emerging trends in translational research in oncology through the implementation of these technologies.
View Article and Find Full Text PDFBackground: This paper is a narrative review of a major clinical challenge at the heart of breast cancer care: determining which patients are at risk of recurrence, which require systemic therapy, and which remain at risk in the survivorship phase of care despite initial therapy.
Methods: We review the literature on prognostic and predictive biomarkers in breast cancer with a focus on detection of minimal residual disease.
Results: While we have many tools to estimate and refine risk that are used to individualize local and systemic therapy, we know that we continue to over treat many patients and undertreat others.